Sylvamo Corp·4

May 18, 11:54 AM ET

Bruce Lizanne M 4

4 · Sylvamo Corp · Filed May 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Sylvamo (SLVM) Director Bruce Lizanne M Receives RSU Award

What Happened

  • Bruce Lizanne M, a director of Sylvamo Corp (SLVM), was granted 3,876 time‑based restricted stock units (RSUs) on 2026-05-15. The grant value is reported at $38.70 per share, totaling $150,001. The transaction is reported as an award/grant (code A), not a purchase or sale.

Key Details

  • Transaction date and price: 2026-05-15 at $38.70 per share (total $150,001).
  • Transaction type: Award/Grant (A) — time‑based RSUs.
  • Vesting/settlement: RSUs vest and will settle one‑for‑one into common stock upon the earlier of May 13, 2027, or the next annual shareowners meeting (footnote).
  • Shares owned after transaction: Not specified in the filing.
  • Filing date/timeliness: Form 4 filed 2026-05-18 (filing appears to be within the normal 2-business-day reporting window).
  • No 10b5-1 trading plan, sale, gift, or tax-withholding detail was disclosed in the filing.

Context

  • These RSUs are a form of director compensation and will convert to common shares only after vesting; they are not an immediate market purchase or sale. Such awards are common for non-employee directors and are typically routine compensation rather than a direct trading signal.

Insider Transaction Report

Form 4
Period: 2026-05-15
Transactions
  • Award

    Common Stock

    [F1]
    2026-05-15$38.70/sh+3,876$150,00115,705 total
Footnotes (1)
  • [F1]The reported securities represent time-based restricted stock units ("RSUs") that were granted to the reporting person for service as a director for the 2026-2027 performance year. The RSUs will vest and settle one-for-one in common stock upon the earlier of May 13, 2027, or the next annual shareowners meeting.
Signature
/s/ Erin Raccah, attorney in fact for Lizanne M. Bruce|2026-05-18

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT